MedTrace Logo

Efficacy of Allopurinol and Dypiridamole in Acute Mania

NCT00560079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-08-16

No results posted yet for this study

Summary

This study aims to evaluate the potential antimanic efficacy, safety and tolorability of the purinergic agents allopurinol and dipyridamole as an add-on treatment to lithium in a sample of 180 drug-free manic patients enrolled in a double-blind, placebo-controlled design.

Conditions

Interventions

DRUG

Allopurinol

Allopurinol 600mg/day bid for 28 days

DRUG

Dipyridamole

Dipyridamole 200mg/day bid for 28 days

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Hospital Espirita de Porto Alegre

    lead OTHER

Principal Investigators

  • Rodrigo Machado-Vieira, MD, MSc, PhD · Staff Member

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2005-04-30
Completion
2006-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00560079 on ClinicalTrials.gov